title: Non-small-cell lung cancer: which platinum for gemcitabine?
authors.affiliation: Department of Oncology, S. Maria Nuova Hospital, Reggio Emilia, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Boni
authors.forename: F
authors.initials: F
authors.lastname: Zanelli
authors.forename: M
authors.initials: M
authors.lastname: Ambroggi
authors.forename: A
authors.initials: A
authors.lastname: Bologna
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004357:Drug Synergism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D017671:Platinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D016019:Survival Analysis; D000093542:Gemcitabine
chemical_list: D017671:Platinum Compounds; D003841:Deoxycytidine; D000093542:Gemcitabine